Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer.

Thumbnail
View/Open
Accepted version (453.2Kb)
Date
2018-09
ICR Author
Chisholm, Julia
Author
Moreno, L
Casanova, M
Chisholm, JC
Berlanga, P
Chastagner, PB
Baruchel, S
Amoroso, L
Gallego Melcón, S
Gerber, NU
Bisogno, G
Fagioli, F
Geoerger, B
Glade Bender, JL
Aerts, I
Bergeron, C
Hingorani, P
Elias, I
Simcock, M
Ferrara, S
Le Bruchec, Y
Slepetis, R
Chen, N
Vassal, G
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background nab-Paclitaxel has demonstrated efficacy in adults with solid tumours and preclinical activity in paediatric solid tumour models. Results from phase I of a phase I/II study in paediatric patients with recurrent/refractory solid tumours treated with nab-paclitaxel are reported.Patients and methods Patients with recurrent/refractory extracranial solid tumours received nab-paclitaxel on days 1, 8 and 15 every 4 weeks at 120, 150, 180, 210, 240, or 270 mg/m 2 (rolling-6 dose-escalation) to establish the maximum tolerated dose (MTD) and recommended phase II dose (RP2D).Results Sixty-four patients were treated. Dose-limiting toxicities were grade 3 dizziness at 120 mg/m 2 and grade 4 neutropenia >7 days at 270 mg/m 2 . The most frequent grade 3/4 adverse events were haematologic, including neutropenia (36%), leukopenia (36%) and lymphopenia (25%). Although the MTD was not reached, 270 mg/m 2 was declared non-tolerable due to grade 3/4 toxicities during cycles 1-2 (neutropenia, n = 5/7; skin toxicity, n = 2/7; peripheral neuropathy, n = 1/7). Of 58 efficacy-evaluable patients, complete response occurred in one patient (2%; Ewing sarcoma) and partial responses in four patients (7%; rhabdomyosarcoma, Ewing sarcoma, renal tumour with pulmonary metastases [high-grade, malignant] and sarcoma not otherwise specified); all responses occurred at ≥210 mg/m 2 . Thirteen patients (22%) had stable disease (5 lasting ≥16 weeks) per RECIST.Conclusions nab-Paclitaxel 240 mg/m 2 qw3/4 (nearly double the adult recommended monotherapy dose for this schedule in metastatic breast cancer) was selected as the RP2D based on the tolerability profile, pharmacokinetics and antitumour activity. Phase II is currently enrolling patients with recurrent/refractory neuroblastoma, rhabdomyosarcoma and Ewing sarcoma. CLINICALTRIALS.GOV: NCT01962103.Eudract 2013-000144-26.
URI
https://repository.icr.ac.uk/handle/internal/2979
DOI
https://doi.org/10.1016/j.ejca.2018.05.002
Collections
  • Clinical Studies
  • Molecular Pathology
Subject
Humans
Neoplasms
Paclitaxel
Albumins
Antineoplastic Agents, Phytogenic
Treatment Outcome
Drug Administration Schedule
Maximum Tolerated Dose
Age Factors
Time Factors
Adolescent
Child
Child, Preschool
Canada
United States
Europe
Female
Male
Drug Dosage Calculations
Research team
Sarcoma Clinical Trials in children and young people
Language
eng
Date accepted
2018-05-01
License start date
2018-09
Citation
European journal of cancer (Oxford, England : 1990), 2018, 100 pp. 27 - 34

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.